| P50 | author | John D Hainsworth | Q73567269 |
| P2093 | author name string | David R Spigel | |
| | James D Bearden | |
| | F Anthony Greco | |
| | Elizabeth R Vazquez | |
| | Eric Raefsky | |
| | Ruben A Saez | |
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions | Q27824806 |
| | Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine | Q33344258 |
| | Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia | Q33499555 |
| | Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 |
| | Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 |
| | Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. | Q40481231 |
| | Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network | Q40517795 |
| | Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules | Q40665828 |
| | Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). | Q44071979 |
| | Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia | Q44688907 |
| | Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. | Q44892386 |
| | Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival | Q45287934 |
| | CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma | Q77435839 |
| | Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria | Q79281118 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| | lymphocyte | Q715347 |
| | chronic lymphocytic leukemia | Q1088156 |
| | patient | Q181600 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 1288-1295 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network | |
| P478 | volume | 112 | |